What Drives Public Preference for Rare Drugs Coverage in China? Insights From a Multi-Center Discrete Choice Experiment

Abstract

Introduction: Reimbursement decisions for orphan drugs are complex, as conventional cost-effectiveness frameworks may not fully capture broader societal values. To investigate public preferences regarding the inclusion of rare disease drugs in China's Basic Medical Insurance (BMI) using a multi-center discrete choice experiment. Methods: From July to September 2024, a face-to-face, filed-based discrete choice experiment (DCE) was conducted across four regions in China. Using non probability sampling technique which is known as Quota sampling, participants evaluated drug profiles varying in six attributes. Mixed logit model and latent class model were used for analysis. Relative importance, w..